IntrinsicIntrinsic
← Scroll for more →

JBT MAREL Corp (JBTM)

Business Summary

JBT Marel Corporation is a leading and diversified global technology solutions and service provider to high-value segments of the food and beverage industry, designing, producing, and servicing sophisticated products and systems for multi-national and regional customers. The company operates in highly competitive markets, competing with large multinational companies as well as a variety of local and regional companies of various sizes and cost structures, typically focused on a specific application, technology, or geographical area. The industry is characterized by competition based on leveraging industry expertise to provide differentiated and proprietary technology, integrated systems, high product quality and reliability, and comprehensive aftermarket services for installed equipment bases.

JBT Marel's major competitors include Advanced Equipment Inc., Alit SRL, Allpax Products, Inc., Atlas Pacific Engineering Company, Inc., Baader GmbH & Co. KG, Barry-Wehmiller Companies, Inc., Brown International Corp., Bühler Group, DSI Dantech A/S, Duravant LLC, Elettric 80 S.p.a. Italia, Ferrum, Fortifi Food Processing Solutions, FPS Process Foods Solutions, GEA Group AG, Heinen Freezing GmbH & Co. KG, Jarvis Products Corporation, Krones, METALQUIMIA, S.A., Mettler-Toledo International, Inc., Meyn Food Processing Technology B.V., Middleby Corporation, Morris & Associates, Inc., MYCOM, Nantong Freezing Equipment Company, Ltd., Poly-clip system GmbH & Co. KG, ProMach Inc, Provisur Technologies, Inc., Shibuya Corporation, Square Technology Group Co., Ltd, Starfrost, Statco Engineering, Steriflow SAS., Tecnopool S.p.A, and Tetra Laval. The company competes by leveraging its industry expertise to provide differentiated and proprietary technology, integrated systems, high product quality and reliability, and comprehensive aftermarket services for its installed base of equipment, which also provides strong, long-term customer relationships from which it derives information for new product development.

JBT Marel generates revenue through the design, production, and servicing of sophisticated products and systems for food and beverage companies, with a mix of recurring and transactional income. Recurring revenue accounted for 50% of total revenue in 2025, derived from aftermarket parts and service offerings and re-build services for customer-owned equipment, supported by a large installed base of systems and equipment. The company also offers full service operating leases on certain high-capacity industrial extractors, which include routine parts and maintenance support. Primary customer segments include multi-national and regional customers in the food and beverage industry, and the company operates through two reportable segments: Protein Solutions and Prepared Food and Beverage Solutions.

The Protein Solutions segment includes businesses that provide solutions for initial stage processing and harvesting of animal proteins, primarily focusing on poultry, pork, fish, and beef, with core technologies including primary processing systems, cut-up, bone detection and removal, portioning, and robotic batching. For the year ended December 31, 2025, Protein Solutions segment revenue was $1,716.2 million , and segment Adjusted EBITDA was $344.7 million with a segment Adjusted EBITDA margin of 20.1% . The Prepared Food and Beverage Solutions segment includes businesses that offer solutions predominantly for downstream value-added preparation, preservation, and packaging of foods and beverages into ready to eat or drink products, also including capabilities for pet food, dairy, bakery, pharmaceutical and nutraceutical, and warehouse automation end markets, with core technologies including meat preparation, forming, cutting, slicing, cooking, freezing, extraction, blending, filling, preservation, labeling, packaging, and automated guided vehicles. For the year ended December 31, 2025, Prepared Food and Beverage Solutions segment revenue was $2,082.0 million , and segment Adjusted EBITDA was $358.7 million with a segment Adjusted EBITDA margin of 17.2% .

On January 2, 2025, the company completed the acquisition of Marel hf., achieving acceptance of the Offer by Marel shareholders representing approximately 97.5% of Marel's issued and outstanding common shares, and on February 4, 2025, acquired the remaining 2.5% of Marel's issued and outstanding common shares. The total consideration for the Marel Transaction and Squeeze out was $4.4 billion , comprised of $1.0 billion of cash consideration paid to the Marel Shareholders, $0.9 billion for repayment of Marel's debt, and $2.5 billion from the issuance of the company's common stock. In connection with the Marel Transaction, on January 2, 2025, the company secured takeout financing comprised of the $900 million Senior Secured Term Loan B and the Second Amended and Restated Credit Agreement, which increased the borrowing limit of the company's revolving credit facility from $1.3 billion to $1.8 billion . The company issued 19,979,633 shares of its common stock to Marel shareholders for the Marel Transaction and Squeeze out, representing approximately 38 percent of its ownership in the combined company upon completion of the issuance. On September 9, 2025, the company closed a private offering of $575.0 million aggregate principal amount of the 2030 Convertible Senior Notes. On February 4, 2025, the company transferred its remaining obligations related to the U.S. qualified defined benefit pension plan to an insurance company through the purchase of an irrevocable group annuity contract.

Total revenue in 2025 increased $2,082.2 million or 121.3% compared to 2024, driven by the acquisition of Marel which provided additional revenue of $1,966.0 million . Gross profit margin decreased 140 bps to 35.1% compared to 36.5% in 2024. Loss from continuing operations for the year ended December 31, 2025 was $49.7 million compared to income from continuing operations of $84.6 million in 2024, representing a decrease of $134.3 million . Adjusted EBITDA was $600.4 million for the year ended December 31, 2025 compared to $295.0 million in 2024, representing an increase of $305.4 million or 103.5% . Adjusted EBITDA margin decreased 140 bps to 15.8% compared to 17.2% in 2024.

Business Outlook & Financial Sufficiency

The company's strategy capitalizes on favorable trends and its leadership position in the food and beverage processing industry, based on a five-pronged approach to deliver continued growth and margin expansion: strengthening solutions and value proposition, enhancing service offerings and customer relationships, advancing digital and software capabilities, focusing on innovation, and leveraging scale to expand margins. The company believes that effective backlog conversion and healthy demand will help deliver year-over-year revenue growth for full year 2026. The company is also focused on improving year-over-year margins through ongoing execution of synergy cost savings projects coupled with volume leverage and continuous improvement efficiencies. The company expects to convert 85% to 95% of backlog at December 31, 2025 into revenue during 2026.

The company's margin performance benefited from realized synergy savings and continuous improvement initiatives. The company is focused on improving year-over-year margins through ongoing execution of synergy cost savings projects coupled with volume leverage and continuous improvement efficiencies. Cumulative cost savings for the JBT Marel 2025 Integration restructuring plan are expected to be between $65.0 million and $75.0 million .

The company anticipates capital expenditures to be between $105 million and $115 million during 2026. During 2026, the company also expects to incur integration costs and other synergy-related costs in the range of $45 million to $55 million related to the acquisition of Marel. The company expects to recognize the remaining restructuring costs for the JBT Marel 2025 Integration restructuring plan by the end of 2026.

Based on the company's current capital allocation objectives for the combined company, capital expenditures are anticipated to be between $105 million and $115 million during 2026. The company's level of capital expenditures varies from time to time as a result of actual and anticipated business conditions. The company does not currently have an active share repurchase program.

The company's 2025 financial performance was driven by strong demand, particularly for poultry solutions, healthy backlog conversion, and successful execution of margin improvement initiatives. The company experienced resilient demand for its aftermarket parts and service products, generating approximately 50% of total revenue from recurring revenue. Additionally, equipment orders from the poultry end market were robust with healthy equipment demand from other diversified end markets, including meat, beverages, ready meals, and pharmaceuticals.

Management Sentiments & Priorities

Management's message emphasizes that the company's 2025 financial performance was driven by strong demand, particularly for poultry solutions, healthy backlog conversion, and successful execution of margin improvement initiatives, with resilient demand for aftermarket parts and service products generating approximately 50% of total revenue from recurring revenue. For full year 2026, management believes that effective backlog conversion and healthy demand will help deliver year-over-year revenue growth, and the company is focused on improving year-over-year margins through ongoing execution of synergy cost savings projects coupled with volume leverage and continuous improvement efficiencies. The strategic priorities emphasized for the period ahead include strengthening solutions and value proposition, enhancing service offerings and customer relationships, advancing digital and software capabilities, focusing on innovation, and leveraging scale to expand margins.

Financial Details

Total revenue for the year ended December 31, 2025 was $3,798.2 million compared to $1,716.0 million in 2024. Net loss from continuing operations was $49.7 million in 2025 compared to net income from continuing operations of $84.6 million in 2024. Diluted loss per share from continuing operations was $0.96 in 2025 compared to diluted earnings per share from continuing operations of $2.63 in 2024. Operating income was $189.4 million in 2025 compared to $118.4 million in 2024. Adjusted EBITDA from continuing operations was $600.4 million in 2025 compared to $295.0 million in 2024. Cash provided by continuing operating activities was $341.7 million in 2025 compared to $232.6 million in 2024. The loss from continuing operations was significantly impacted by a pension settlement charge of $146.9 million recognized in the first quarter of 2025 upon the termination of the U.S. qualified defined benefit pension plan, compared to $23.3 million of settlement charges recognized in 2024. The Protein Solutions segment reported revenue of $1,716.2 million and segment Adjusted EBITDA of $344.7 million in 2025, while the Prepared Food and Beverage Solutions segment reported revenue of $2,082.0 million and segment Adjusted EBITDA of $358.7 million .

Risk Factors

The company faces risks related to its substantial indebtedness, which increased following the Marel Transaction, with total debt of $1,910.3 million as of December 31, 2025, including $932.8 million in variable rate debt subject to floating rates, which could adversely impact operational flexibility and increase borrowing costs. The company may not realize some or all of the expected benefits and synergies from the Marel Transaction, with integration costs expected in the range of $45 million to $55 million during 2026, and the total estimated cost for the JBT Marel 2025 Integration restructuring plan was updated to a range of $55.0 million to $60.0 million . Material weaknesses were identified in Marel's internal control over financial reporting, specifically related to information technology general controls and controls over the recording and review of journal entries, which remained unremediated as of December 31, 2025. The company's goodwill and intangible assets represent approximately 68% of total assets as of December 31, 2025, and future impairment charges could materially affect reported net income if estimates or underlying assumptions change.

References

  1. [1] Item 7, MD&A — Operating Results of Business Segments
  2. [2] Item 7, MD&A — Operating Results of Business Segments
  3. [3] Item 7, MD&A — Operating Results of Business Segments
  4. [4] Item 7, MD&A — Operating Results of Business Segments
  5. [5] Item 7, MD&A — Operating Results of Business Segments
  6. [6] Item 7, MD&A — Operating Results of Business Segments
  7. [7] Item 1, Business — Strategic Acquisition of Marel hf.
  8. [8] Item 1, Business — Strategic Acquisition of Marel hf.
  9. [9] Item 1, Business — Strategic Acquisition of Marel hf.
  10. [10] Item 1, Business — Strategic Acquisition of Marel hf.
  11. [11] Item 1, Business — Strategic Acquisition of Marel hf.
  12. [12] Item 1, Business — Strategic Acquisition of Marel hf.
  13. [13] Item 1, Business — Strategic Acquisition of Marel hf.
  14. [14] Item 1, Business — Strategic Acquisition of Marel hf.
  15. [15] Item 1, Business — Strategic Acquisition of Marel hf.
  16. [16] Item 1, Business — Strategic Acquisition of Marel hf.
  17. [17] Item 1, Business — Strategic Acquisition of Marel hf.
  18. [18] Item 7, MD&A — Financing Arrangements
  19. [19] Item 7, MD&A — Consolidated Results of Operations
  20. [20] Item 7, MD&A — Consolidated Results of Operations
  21. [21] Item 7, MD&A — Consolidated Results of Operations
  22. [22] Item 7, MD&A — Consolidated Results of Operations
  23. [23] Item 7, MD&A — Consolidated Results of Operations
  24. [24] Item 7, MD&A — Consolidated Results of Operations
  25. [25] Item 7, MD&A — Consolidated Results of Operations
  26. [26] Item 7, MD&A — Consolidated Results of Operations
  27. [27] Item 7, MD&A — Reconciliation of Non-GAAP Measures
  28. [28] Item 7, MD&A — Reconciliation of Non-GAAP Measures
  29. [29] Item 7, MD&A — Reconciliation of Non-GAAP Measures
  30. [30] Item 7, MD&A — Reconciliation of Non-GAAP Measures
  31. [31] Item 7, MD&A — Consolidated Results of Operations
  32. [32] Item 7, MD&A — Consolidated Results of Operations
  33. [33] Item 7, MD&A — Inbound Orders and Order Backlog
  34. [34] Item 7, MD&A — Restructuring
  35. [35] Item 7, MD&A — Restructuring
  36. [36] Item 7, MD&A — Liquidity and Capital Resources
  37. [37] Item 7, MD&A — Liquidity and Capital Resources
  38. [38] Item 7, MD&A — Liquidity and Capital Resources
  39. [39] Item 7, MD&A — Liquidity and Capital Resources
  40. [40] Item 7, MD&A — Liquidity and Capital Resources
  41. [41] Item 7, MD&A — Liquidity and Capital Resources
  42. [42] Item 7, MD&A — Business Conditions and Outlook
  43. [43] Item 7, MD&A — Contractual Obligations and Cash Requirements
  44. [44] Item 7A, Quantitative and Qualitative Disclosures About Market Risk
  45. [45] Item 7, MD&A — Liquidity and Capital Resources
  46. [46] Item 7, MD&A — Liquidity and Capital Resources
  47. [47] Item 7, MD&A — Restructuring
  48. [48] Item 7, MD&A — Restructuring
  49. [49] Item 1A, Risk Factors — Business Strategy Risks
  50. [50] Item 7, MD&A — Business Conditions and Outlook
  51. [51] Item 8, Consolidated Statements of Income
  52. [52] Item 8, Consolidated Statements of Income
  53. [53] Item 8, Consolidated Statements of Income
  54. [54] Item 8, Consolidated Statements of Income
  55. [55] Item 8, Consolidated Statements of Income
  56. [56] Item 8, Consolidated Statements of Income
  57. [57] Item 8, Consolidated Statements of Income
  58. [58] Item 8, Consolidated Statements of Income
  59. [59] Item 7, MD&A — Reconciliation of Non-GAAP Measures
  60. [60] Item 7, MD&A — Reconciliation of Non-GAAP Measures
  61. [61] Item 8, Consolidated Statements of Cash Flows
  62. [62] Item 8, Consolidated Statements of Cash Flows
  63. [63] Item 7, MD&A — Consolidated Results of Operations
  64. [64] Item 7, MD&A — Consolidated Results of Operations
  65. [65] Item 7, MD&A — Operating Results of Business Segments
  66. [66] Item 7, MD&A — Operating Results of Business Segments
  67. [67] Item 7, MD&A — Operating Results of Business Segments
  68. [68] Item 7, MD&A — Operating Results of Business Segments

Analysis on 9/28/2026